Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. 

Medical Devices

Hologic

Ms. Stewart has been a member of our board since January 2023. Ms. Stewart previously served as President & CEO of March of Dimes Inc., a leading nonprofit organization, from November 2016 to December 2022. From June 2009 to November 2016, Ms. Stewart served ina variety of executive positions, including U. S. President of operations and executive vice president for Community Impact Leadership and Learning, at United Way Worldwide, the world's largest charitable organization. From February 2007 to April 2009, Ms. Stewart was a senior vice president of Fannie Mae, a government-sponsored enterprise that supports liquidity and stability in the secondary mortgage market. Ms. Stewart is a director of PennyMac Mortgage Investment Trust. Ms. Stewart holds a Bachelor of Arts from Georgetown University and a Master of Business Administration from the University of Michigan.

Stacey D. Stewart

Ms. Crawford became a member of the board effective upon the merger with Cytyc Corporation ('Cytyc") in October 2007, having previously served as a director of Cytyc since January 1998. From April 1985 until January 1997, Ms. Crawford served as Chief Operating Officer of Healthsource, Inc., a publicly held managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., Ms. Crawford held a variety of positions and responsibilities, including leading that company's Northern Region operations and marketing efforts. Since January 1997, Ms. Crawford has been a healthcare consultant in New Hampshire. Ms. Crawford serves as a director of Abcam plc, where she is a member of the Remuneration and Audit and Risk Committees, and as a director of ZimVie Inc. where she is a member of the Audit, Corporate Governance and Quality, Regulatory, and Technology Committees and chair of the Compensation Committee. Ms. Crawford previously served as a director of Insulet Corporation, Universal American Corporation, Exact Sciences Corporation, Chittenden Corporation, and Zalicus Inc. (now EPIRUS Biopharmaceuticals, Inc.) Ms. Crawford earned a bachelor's degree from Smith College and a master's degree in communications from Boston University.

Sally W. Crawford

Ms. Wendell was appointed to the Board in December 2016. From January 2016 to May 2019, Ms. Wendell was a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice, providing guidance and advice with respect to mergers and acquisitions and divestures for clients and assisting the firm in connection with firm-level transactions. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice and also served as a member of McKinsey's Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management, and business development. Most recently, from December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures, and licensing/distribution. Ms. Wendell also serves as Lead Director of AxoGen, Inc., where she is a member of the Nominating and Governance Committee and the Compensation Committee, and at Baxter International, Inc., where she is a member of the Quality. Compliance and Technology Committee. She is Chairman of the Board of Por Cristo, a non- proft charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.

Amy M. Wendell

Paul Malenchini is currently the Chief Information Officer at [Hologic](/org/hologic). Previously, they served as the VP of Consulting at TriCore Solutions from January 2005 to February 2008, and as the President and CEO of Core Apps from October 2001 to January 2005. In their role as President and CEO of Core Apps, Paul was responsible for executing a merger between Core Apps and TriCore Solutions, as well as scaling the company beyond New England and into the Mid West region. Prior to their work at Core Apps, Paul served as a Project Manager at Whitbread Technology Partners from January 2000 to December 2001.

Paul Malenchini is a graduate of [Merrimack College](/org/merrimack-college).

Paul Malenchini reports to Stephen P. MacMillan, Chairman, President & CEO. They are on a team with Robert W. McMahon - CFO, Jan Verstreken - Group President, International, and Patrick Brady - SVP, Global Supply Chain, Quality & Regulatory.

Paul Malenchini

John M. Griffin

Erik Anderson was promoted to President, Global Services and Breast & Skeletal Health Service in August 2020.  He joined [Hologic](/org/hologic)’s Breast & Skeletal Health Division in 2014 as Regional Sales Manager for the Upper Midwest, then was promoted to Area Business Director.  In 2017, Mr. Anderson took over as Vice President of Sales for [Hologic](/org/hologic)’s Medical Aesthetics business amid turbulent times, stabilizing and rebuilding the team while also impacting the broader business, leading to his promotion to President of Medical Aesthetics in 2019.   He led the business while also leading [Hologic](/org/hologic)’s divestiture of [Cynosure](/org/cynosure) and its transition to new ownership.  He rejoined [Hologic](/org/hologic) as Vice President, Global Service Initiative and Breast & Skeletal Health Field Service/Technical Support in early 2020, leading new initiatives to increase customer focus and capacity for the Company’s large service, support and customer experience business.  Prior to joining [Hologic](/org/hologic), Mr. Anderson worked at [ImpediMed](/org/impedimed) and Stryker Instruments.  He has a bachelor’s degree in Marketing from [Iowa State University](/org/iowa-state-university), where he was a 4-year letter winner and captain of the football team.

Erik Anderson

Jan Verstreken is the Group President, International at [Hologic](/org/hologic). Jan was previously with Teleflex Incorporated from November 2008 to January 2017 as the President Asia Pacific and General Manager LMA BU.

Jan Verstreken has a degree in marketing from Hoger Handels Instituut Turnhout.

Their manager is Stephen P. MacMillan, Chairman, President & CEO. They work with Michelle Garsha - President, Diagnostic Solutions, Monica Aguirre Berthelot - Senior Assistant, and Paul Malenchini - Chief Information Officer.

Jan Verstreken

Ms. Stamoulis has been a member of the board since November 2011. In February 2019, Ms. Stamoulis assumed the role of Executive Vice President and Chief Financial Officer of Incyte Corporation. From January 2015 to the end of January 2019, Ms. Stamoulis served as Chief Financial Officer of Unum Therapeutics, adding the role of President in February 2018. Prior to Unum, she was an independent advisor to biopharmaceutical companies from January 2014 to December 2014. Prior to that, Ms. Stamoulis served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals Incorporated from 2009 to 2013. Ms. Stamoulis joined Vertex in 2009 with approximately 15 years of experience in the investment banking and management consulting industries where she advised global pharmaceutical and biotechnology companies on strategic and corporate finance decisions. Prior to joining Vertex, she was a Managing Director in the Investment Banking division of Citigroup from 2006 to 2009 where she led the building of the firm's U.S. Life Sciences investment banking practice. Prior to her role at Citigroup, she was at Goldman, Sachs & Co. where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis holds a Bachelor of Science degree in Economics and a Bachelor of Science degree in Architecture from the Massachusetts Institute of Technology (MIT). Additionally, she holds a Master of Business Administration from the MIT Sloan School of Management where she focused on Applied Economics and Finance.

Christiana Stamoulis

Mr. Garrett has been a member of the board since May 2013. Mr. Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners. He joined Water Street in 2011 after approximately 35 years in the global healthcare industry. Prior to joining Water Street, Mr. Garrett served as Chairman, President, and Chief Executive Officer of Beckman Coulter, a leading biomedical company, from 2008 to 2011. Mr. Garrett joined Beckman Coulter in 2002 as President of the Clinical Diagnostics Division and was promoted in 2003 to President and Chief Operating Officer. In January 2005, he became Chief Executive Officer, adding the position of Chairman in 2008. Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to 2001. From 1994 to 1998, Mr. Garrett served as Chairman, President, and Chief Executive Officer of Dade Behring, a leading diagnostics company. He began his career at American Hospital Supply Corporation and continued there after the company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter's global laboratory business, Baxter Diagnostics. Mr. Garrett currently serves on the boards of companies in which Water Street has an ownership interest, including MarketLab Inc. and Orgentec Diagnostics. He also serves as a director of Immucor, Inc. Mr. Garrett received a B.S. in Mechanical Engineering from Valparaiso University and an M.B.A. from Lake Forest Graduate School of Management.

Scott Garrett

Kevin Thornal was promoted to his current position in July 2019. He joined [Hologic](/org/hologic) in 2014 as Vice President, Customer Experience, Field Service and Clinical Applications for the Breast and Skeletal Health division. He transitioned to Vice President, Breast and Skeletal Health for the Europe, Middle East and Africa region in early 2016, and was promoted to President, Medical Aesthetics in July 2017. During his two-year tenure leading the Medical Aesthetics division, he stabilized the business and built a foundation for growth by attracting top talent and rebuilding the innovation pipeline. Prior to joining [Hologic](/org/hologic), Mr. Thornal worked at [Stryker](/org/stryker) from 2004 to 2014 in positions of increasing responsibility in sales, marketing, and mergers and acquisitions. Throughout his career, he has established a track record of leading businesses that deliver strong growth and commercial excellence. Mr. Thornal previously played professional football, including a short stint with the [Atlanta Falcons](/org/atlanta-falcons-football-club-llc). He holds a BA in History, with minors in English and Secondary Education, from [Southern Methodist University](/org/southern-methodist-university).

Kevin R. Thornal

Steve MacMillan joined [Hologic](/org/hologic) in December 2013 as President and CEO, and has led a dramatic turnaround at the Company. He was elected Chairman of the Board of Directors in June 2015. From 2005 to 2012, Mr. MacMillan served as President and Chief Executive Officer of [Stryker](/org/stryker), where he had been President since 2003. During his tenure at [Stryker](/org/stryker), Mr. MacMillan successfully led the company through a series of key strategic acquisitions, the launch of a number of products within the orthopedic implants and medical instrumentation businesses, and delivered strong operating performance, with revenue tripling from $2.8 billion to $8.3 billion between 2003 and 2011. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia, where he oversaw five global businesses with revenues exceeding $2 billion, including one in diagnostics. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with [Johnson & Johnson](/org/johnson-johnson) in a variety of senior roles both in the US and Europe, including President of the joint venture between [Johnson & Johnson](/org/johnson-johnson) and [Merck](/org/merck). Mr. MacMillan began his career with [Procter & Gamble](/org/procter-gamble) in 1985. He received a BA degree in Economics from [Davidson College](/org/davidson-college), and is a graduate of [Harvard Business School](/org/harvard-business-school)’s Advanced Management Program. Mr. MacMillan serves on the board of directors of Boston Scientific Corporation, and previously served on the Boards of Alere and [Texas Instruments](/org/texas-instruments).

Stephen P. MacMillan

Mr. Nawana was appointed to the Board in January 2018. Mr. Nawana is Executive Chairman, Founder, and a member of the Board of Directors of Sapphiros. He was formerly the Chief Executive Officer and member of the Board of Directors of Smith & Nephew plc. Mr. Nawana was Chief Executive Officer, President, and a member of the Board of Directors of Alere, Inc. from October 2014 until October 2017, when Alere was acquired by Abbott Laboratories. Mr. Nawana joined Alere as Chief Operating Officer in December 2012 before being named Interim Chief Executive Officer in July 2014. Before joining Alere, Mr. Nawana spent 15 years at Johnson & Johnson in various leadership roles. Most recently, he served as the Worldwide President of DePuy Synthes Spine, a Johnson & Johnson company, from February 2011 to November 2012. Prior to that, Mr. Nawana served as Area Vice President for Johnson & Johnson Medical in Australia and New Zealand from January 2009 to February 2011, Chairman of the DePuy Asia Pacific Franchise Council, General Manager for DePuy Australia from 2007 to December 2008, and General Manager for DePuy Canada from 2004 to 2007. Mr. Nawana holds an Honors degree in Mechanical Engineering and a Master of Medical Science from the University of Adelaide, South Australia, and a Master of Business Administration from Henley Management College.

Namal Nawana

Dr. Hantson was appointed to the Board in November 2018. Dr. Hantson was formerly Chief Executive Officer of Alexion Pharmaceuticals, Inc. from March 2017 to July 2021, when Alexion was acquired by Astraženeca PLC. Prior to joining Alexion, he was President and Chief Executive Officer of Baxalta Incorporated. In July 2015, Dr. Hantson led Baxalta's successful spin-off as a public company from Baxter International Inc., where he was President of Baxter BioScience. He joined Baxter in May 2010 and established the BioScience division as an innovative specialty and rare disease company. Prior to Baxter, from 2001- 2010, Dr. Hantson held several leadership roles at Novartis AG, including CEO of Pharma North America, CEO of Europe, and President of Pharma Canada. Prior to Novartis, he spent 13 years with Johnson & Johnson in roles of increasing responsibility in marketing and R&D. Dr. Hantson previously served on the board of Baxalta. He received his Ph.D. in motor rehabilitation and physical therapy, a master's degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.

Ludwig N. Hantson

Mr. Dockendorff has been a member of the board since May 2017. Mr. Dockendorff was formerly Executive Vice President and Chief Financial Officer of Covidien plc, a global medical device, and supplies company. He was CFO at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorf joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. Prior to joining Kendalli/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance, and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation. Mr. Dockendoff is a director of Boston Scientific Corporation, Haemonetics Corporation, and Keysight Technologies, Inc. Mr. Dockendorff holds a bachelor's degree in accounting from the University of Massachusetts at Amherst and an M.S. in finance from Bentley College.

Charles J. Dockendorff

Paula Izidoro is the current Manager of Investor Relations and Social Media at [Hologic](/org/hologic). Paula has worked in many different aspects of business, including executive assistance, marketing communications, and creative services coordination. Paula has been with [Hologic](/org/hologic) since 2003 and has been an integral part of the company's success. In their previous positions, they have provided essential support to the Chief Financial Officer and Vice President of Investor Relations, as well as being a member of the Community Relations, Activities Committee, and Travel Committee. Paula's experience and dedication make their an asset to any company.

Paula Izidoro has an AA in Marketing from FIDM and a certification from the State of California in Notary Public.

Paula Izidoro reports to Francis Pruell, Director, Investor Relations.

Paula Izidoro

Monica Aguirre Berthelot is a senior assistant at Hologic, Inc. Monica has previously worked for the company in various capacities, including as a sales representative and product manager.

Some of their coworkers include John M. Griffin - General Counsel, Robert W. McMahon - CFO, and Essex Mitchell - Division President, GYN Surgical Solutions. Monica Aguirre Berthelot reports to Stephen P. MacMillan, Chairman, President & CEO.

Monica Aguirre Berthelot

Robert W. McMahon is the Chief Financial Officer at [Hologic](/org/hologic). Robert has been in this role since June 2014 and is responsible for the financial performance of the company. Prior to joining [Hologic](/org/hologic), McMahon served as Worldwide Vice President of Finance for [Ortho Clinical Diagnostics](/org/ortho-clinical-diagnostics) at [Johnson & Johnson](/org/johnson-johnson). In this role, they were responsible for providing financial leadership and was a member of the Global Management Board. Robert also led a team of approximately 100 finance professionals around the world. McMahon began their career as a cost accountant at Harris Corporation.

Robert W. McMahon has an MBA in Finance from the [University of Central Florida](/org/university-of-central-florida) and a BSBA in Finance from the University of Florida - Warrington College of Business. Robert is also certified as a Certified Management Accountant from the Institute of Management Accountants (IMA).

Some of their coworkers include Jan Verstreken - Group President, International, Essex Mitchell - Division President, GYN Surgical Solutions, and Patrick Brady - SVP, Global Supply Chain, Quality & Regulatory. Their manager is Stephen P. MacMillan, Chairman, President & CEO.

Robert W. McMahon

Essex Mitchell was born on October 10, 1978 in Detroit, Michigan. Essex played football for both the Canadian Football League and the National Football League before starting their career in sales. Essex has worked as a Pediatric Vaccine Specialist for [Merck](/org/merck), a Consumer Products-Retail Sales Representative for Abbott Nutrition, and a General Manager for Joint Replacement / Trauma & Extremities at [Stryker](/org/stryker). Essex is currently the Division President for GYN Surgical Solutions at [Hologic](/org/hologic).

Essex Mitchell has a BSBA from The Ohio State University Fisher College of Business and an Executive Education from [Stryker](/org/stryker) Leadership at Harvard. Essex also has a Financial Management Certificate from [Cornell University](/org/cornell-university).

Essex Mitchell reports to Stephen P. MacMillan, Chairman, President & CEO. They work with Karleen Oberton - Chief Accounting Officer, John M. Griffin - General Counsel, and Jennifer Meade - Division President, Breast & Skeletal Health Solutions.

Essex Mitchell

Francis Pruell is the Director of Investor Relations at [Hologic](/org/hologic). Francis has over 10 years of experience in the financial industry. Francis started their career as a Senior Financial Analyst at Raytheon Network Centric Systems and then moved to EMC as a Principal Treasury Analyst, Capital Markets. In 2016, they joined [Analysis Group](/org/analysis-group) as an Associate. Francis has been with [Hologic](/org/hologic) since January 2018.

Francis Pruell has a Master of Business Administration (M.B.A.) from Northwestern University - Kellogg School of Management, a MA in Economics from [Northeastern University](/org/northeastern-university), and a BA in Business Economics with a Minor in Finance from [Providence College](/org/providence-college). Francis also has certification from the [CFA Institute](/org/cfa-institute) as a CFA Charterholder.

and Paula Izidoro - Manager, Investor Relations & Social Media reports to Francis Pruell. Francis Pruell reports to Ryan Simon, VP, Investor Relations.

Francis Pruell

Karleen Oberton was the Sr Director, Corporate Controller at ImmunoGen, Inc. from February 2004 to May 2006. Karleen is currently the Chief Accounting Officer at [Hologic](/org/hologic).

Karleen Oberton attended [Merrimack College](/org/merrimack-college) for their undergraduate degree. Karleen then attended [Boston University](/org/boston-university) for their graduate degree.

Karleen Oberton reports to Stephen P. MacMillan, Chairman, President & CEO. Karleen Oberton works with Erik Anderson - President, Global Services, Jan Verstreken - Group President, International, and Essex Mitchell - Division President, GYN Surgical Solutions.

Karleen Oberton

Ryan Simon

Lisa Hellmann was promoted to Senior Vice President, Human Resources in June of 2021. Previously, she served as both Vice President of Human Resources for [Hologic](/org/hologic)’s Diagnostics division and Head of Global Internal Communications. As a strategic and trusted partner to her customers and colleagues, she helps build and sustain high-performing teams through a positive employee experience, organizational effectiveness, and a strong company culture. Before re-joining [Hologic](/org/hologic) in 2017, Ms. Hellmann held various HR positions of broad and increasing responsibility at Gen-Probe and other innovative biotech companies and laboratories. She earned a BA in Human Biology from Stanford and a master’s degree in Global HR Leadership from Rutgers.

Lisa Hellmann

Pat Brady joined [Hologic](/org/hologic) in October 2018 with more than 22 years of medical devices experience. From 1996 to 2018, Mr. Brady worked at [Johnson & Johnson](/org/johnson-johnson) in various roles of increasing responsibility. Most recently, he served as the Worldwide Vice President Manufacturing for [Johnson & Johnson](/org/johnson-johnson)’s Global Orthopaedics business. Prior to that, Mr. Brady was the Worldwide Vice President Manufacturing for DePuy, a J&J Company and served as the end-to-end supply chain leader on the global management boards of the Joint Reconstruction and Codman Neuro divisions. Earlier in his career, he held management positions in operations and quality at General Electric - Aircraft Engine Division.

Mr. Brady has a BS in Mechanical Engineering from [Worcester Polytechnic Institute](/org/worcester-polytechnic-institute) and an MBA from the Boston College Carroll School of Management.

Patrick Brady

The leadership team at Hologic has a history of experience in finance, accounting, marketing, and sales. They have also worked in various industries, including healthcare, consumer products, and technology. They have attended some of the world's most prestigious universities, including UCF, UF, Ohio State, and Harvard.

Leadership Team

About

Team members

Other teams at Hologic

Board of Directors

CEO and Executive Team

Discover similar companies